1. Introduction {#sec1}
===============

Chemotherapy-induced peripheral neuropathy (CIPN) results from toxic effects of chemotherapy drugs predominantly affecting the peripheral nervous system. The associated pain of CIPN can be extremely disabling, with a marked impact on quality of life (Qol), functions of daily living, and increases the risks of noncompliance with cancer treatment \[[@B1]\]. Oxaliplatin (OXAL), a third-generation platinum-based compound, has become pivotal for the therapy of metastatic colorectal cancer and other malignancies including lung, breast, and ovarian cancers \[[@B2], [@B3]\]. However, OXAL induced chronic neurotoxicity occurs in 63.6% or more of patients, which limited the dosing of OXAL \[[@B4]\].

Radix Astragali (the root of*Astragalus mongholicus Bge.*or*Astragalus membranaceus Bge.*) has been used as one of the primary tonic herbs in traditional Chinese and Japanese Kampo medicine. Recently, Radix Astragali (Huangqi, in Chinese) is being widely used, orally or topically, and alone or in combination with western conventional medicine to relieve CIPN. Multiple randomized clinical trials have suggested that Radix Astragali- (RA-) based intervention can reduce symptoms, improve Qol and immunologic function, increase plasma nerve growth factor (NGF) levels, and delay the progression of CIPN \[[@B5]--[@B28]\].*In vivo* RA-based prescription (Huangqi Guizhi Wuwu Decoction) can effectively relieve pain and improve sciatic nerve conduction velocity and function in rats with CIPN \[[@B29], [@B30]\]. Its mechanism may be related to downregulating NR2B expression in L4--6 lumbar spinal segments and upregulating pNF-H protein levels in dorsal root ganglia \[[@B30]\]. However, no systematic review to date has reported effects of RA-based intervention on OXAL induced peripheral neuropathy. In this meta-analysis, the effectiveness and safety of RA-based intervention for preventing and treating OXAL induced peripheral neuropathy are evaluated for the first time.

2. Methods {#sec2}
==========

Ethics data for this study were acquired through previously published work; no patient or hospital data were accessed. Therefore, written consent and institutional ethical review were not required for this research.

2.1. Database and Search Strategies {#sec2.1}
-----------------------------------

The electronic databases of MEDLINE (1982--2015), Cochrane Controlled Trials (2015, Issue 12), Springer (1997--2015), China National Knowledge Infrastructure (CNKI) database (1997--2015), and Wanfang Database of China Science Periodical Database (CSPD) (1998--2015) were searched by using keywords of "Neurotoxicity", "Oxaliplatin" "Astragali", or "Huangqi", without language limitation. Reference lists from trials selected by electronic searching were hand searched. All of those searches ended before January 2016.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

All randomized controlled trials (RCTs) investigating the effects of RA-based Chinese herbal medicine for preventing and treating OXAL induced peripheral neuropathy will be eligible for inclusion.

### 2.2.1. Types of Participants {#sec2.2.1}

All adult patients (18 years and older, no upper age limit) with a treatment of OXAL will be considered for this review. The participants had to conform to the following diagnostic criteria.The patient was clearly diagnosed malignant by pathology or cytology.The patient was treated by OXAL, FOLFOX (OXAL + 5-fluorouracil + calcium folinate), or XELOX (OXAL + capecitabine).Age, gender, stages, and pathological types between the groups were balanced and comparable.

### 2.2.2. Types of Interventions {#sec2.2.2}

RA-based interventions included single herb (including extracts from RA) and a compound of several herbs, irrespective of dosage form (e.g., oral decoction or lotion). The mode of delivery (e.g., oral, topical administration or intravenous) was not restricted. Relative high dose RA (monarch drug) should be included in the prescription and regimen of herbs was not restricted.

The control interventions were placebo, no intervention, or conventional treatment such as mecobalamin, Ca/Mg infusions, or reduced glutathione. We also included trials of RA-based prescription plus conventional medicine versus the same conventional medicine alone.

2.3. Types of Outcome Measures {#sec2.3}
------------------------------

*Grading of CIPN*. Primary outcome was the grading of CIPN in at least 1 chemotherapy cycle, but preferably in 4 cycles of chemotherapy. We considered Levi\'s grade \[[@B31]\], World Health Organization (WHO) grade \[[@B32]\] or National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) for the clinical grading of CIPN \[[@B33]\] ([Table 1](#tab1){ref-type="table"}).

*Clinical Effectiveness*. Clinical effectiveness was assessed according to what is previously described \[[@B32], [@B34]\].

*Complete Remission (CR)*. The patients felt completely free from all symptoms, with the grading of CIPN reduced to grade 0.

*Partial Remission (PR)*. Symptoms abated obviously, and the grading of CIPN reduced ≥1 grade.

*Nonperceptible (NP)*. Compared with before treatment symptoms have not abated, and the grading of CIPN did not reduce.$$\begin{matrix}
{Remission\,\, Rate = CR + PR.} \\
\end{matrix}$$

*Nerve Conduction Velocity*. Changes in values of sensory nerve conduction velocity (SNCV) or motor sensory nerve conduction velocity (MNCV) were measured by validated methods after 1 week of RA treatment or more.

*Quality of Life (Qol) and Adverse Events*. We extracted Qol, measured as Karnofsky (KPS) scale or Eastern Cooperative Oncology Group (ECOG) scale. Adverse events were also extracted.

2.4. Exclusion Criteria {#sec2.4}
-----------------------

We excluded studies with unclear diagnostic criteria and without the use of RA. Combinations of herbs and other forms of treatment (e.g., acupuncture or moxibustion) were excluded.

2.5. Data Extraction and Quality Assessment {#sec2.5}
-------------------------------------------

Data were entered into an electronic database by two authors (Bo Deng and Liqun Jia) independently. Where differences in opinion existed, they were resolved by a third party. Improved Jadad scale was used to assess the quality of RCTs, including randomization, blinding of participants, personnel, and outcome assessors, incomplete outcome data, and other threats to validity \[[@B35]\]. High quality is 4--7 points. Low quality is 1--3 points.

2.6. Data Synthesis {#sec2.6}
-------------------

Review Manager (RevMan) 5.0 software, provided by the Cochrane Collaboration (UK), was used to analyze the results of the trials. Dichotomous data were expressed as odds ratio (OR). Continuous data were expressed as mean difference (MD). Heterogeneity between results of different trials was tested, and heterogeneity was presented as significant when *I* ^2^ is over 50% or *P* \< 0.1. Random effect model was used for the meta-analysis if there was significant heterogeneity and fixed effect model was used when the heterogeneity was not significant \[[@B35]\]. Publication bias was explored via a funnel plot analysis.

3. Results {#sec3}
==========

3.1. Description of Studies and Methodological Quality ([Figure 1](#fig1){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}) {#sec3.1}
---------------------------------------------------------------------------------------------------------------------------------

Our primary searches identified 841 references from the above databases. After duplicates, animal studies, case reports, reviews, and obvious ineligibility were removed, we retrieved a total of 110 references for further assessment. After full-text reviews, 24 trials were included \[[@B5]--[@B28]\]. Included trials were published from 2009 to 2015, with the years 2011 to 2015 having a larger number of trials (20 trials, 85.70% patients) than other years. All trials were conducted in mainland China. Since all included trials were assessed to be of high quality (improved Jadad score of 4 or 5 points), the risk of bias in this systematic review was low. All 24 trials employed computer software or random number tables for randomization. Nine trials used conventional medicine as control, and only one trial performed double-blinding.

3.2. Participants {#sec3.2}
-----------------

In total, 1552 participants with OXAL treatment were included in these 24 trials. The average size of the trials was 66 participants, ranging from 40 to 135 per trial. Eleven trials enrolled only inpatients (*n* = 689 patients, 44.39%). The remaining 13 trials did not specify the setting (*n* = 863 patients, 55.61%). All trials included both adult male and female patients, with 58.63% participants being male. Types of cancer in participants included colorectal cancer (*n* = 1033 patients), gastric cancer (*n* = 399 patients), and lung cancer/breast cancer/other cancers (*n* = 52 patients). The cancers of 68 patients were not specified. Accumulated OXAL dose varied from 130 mg/m^2^ to 800 mg/m^2^, with 260--600 mg/m^2^ (11 trials) being the most common. Eighteen trials used Levi\'s grading of CIPN, 3 used CTCAE criteria of CIPN, and 3 used WHO criteria of CIPN.

3.3. Intervention Comparisons (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}) {#sec3.3}
----------------------------------------------------------------------------------------------------

Sixteen trials (*n* = 1060 patients) compared RA-based intervention with no intervention. Three trials (*n* = 159 patients) tested RA-based prescriptions against mecobalamin. Another 5 trials (*n* = 333 patients) tested RA-based prescriptions in combination treatment remedies compared to the same western medications for CIPN management. Three types of administration methods were employed in these 24 trials, including oral administration (10 trials), topical administration (12 trials), and intravenous drip (1 trial). One trial employed oral administration combined with topical administration. The most popular prescriptions were modified Huangqi Guizhi Wuwu Decoction (7 trials) and modified Buyang Huanwu Decoction (5 trials). Prescriptions composed by the investigators themselves were combined and modified from these 2 prescriptions (10 trials). More than 50% of RA-based prescriptions included Danggui, Guizhi, Baishao, Jixueteng, Chuanxiong, and Honghua. These herbs may augment the effects of RA intervention on CIPN. Doses of RA ranged from 15 g to 180 g but most fell in the range of 30 to 50 g (12 trials). The duration of treatment varied mostly from 2 weeks to 8 chemotherapy cycles. Regarding topical administration, the temperature of decoction ranged from 35°C to 42°C, but most were in the range of 38--42°C (6 trials).

3.4. Effects of Interventions {#sec3.4}
-----------------------------

### 3.4.1. Incidence of All-Grade CIPN ([Figure 2](#fig2){ref-type="fig"}) {#sec3.4.1}

Eighteen trials reported incidence of all-grade (grades 1--4) CIPN. Five trials included CIPN patients and reported curative effects of RA-based prescriptions. And 1 trial only reported incidence of high-grade CIPN. Fifteen trials compared RA-based intervention to no intervention. RA-based intervention significantly reduced CIPN occurrence (*n* = 993 patients; OR, 0.19, 95% CI, 0.14 to 0.25, *P* \< 0.01). One trial compared RA-based prescription to mecobalamin. RA-based prescription significantly reduced CIPN occurrence (*n* = 42 patients; OR, 0.17, 95% CI, 0.03 to 0.94, *P* \< 0.05). Two trials compared RA-based prescriptions plus reduced glutathione or Ca/Mg infusions with the same conventional medications. RA-based prescriptions in combined remedies significantly reduced CIPN occurrence (*n* = 120 patients; OR, 0.42, 95% CI, 0.18 to 0.97, *P* \< 0.05).

### 3.4.2. Incidence of High-Grade CIPN ([Figure 3](#fig3){ref-type="fig"}) {#sec3.4.2}

Nineteen trials reported incidence of high-grade (grades 3-4) CIPN. No patients develop high-grade CIPN in 1 trial. Therefore 18 trials were included in a forest plot. Fourteen trials compared RA-based intervention to no intervention, mostly by using Levi\'s grading (11 trials). RA-based intervention significantly reduced high-grade CIPN (*n* = 931 patients; OR, 0.17, 95% CI, 0.09 to 0.31, *P* \< 0.01). However, 2 trials compared modified RA-based prescriptions to mecobalamin, and 2 trials compared RA-based prescriptions plus reduced glutathione or Ca/Mg infusions with the same conventional medications. In these trials, there was no statistical difference between groups.

### 3.4.3. Curative Effect of RA-Based Prescriptions ([Figure 4](#fig4){ref-type="fig"}) {#sec3.4.3}

Five trials included 341 patients that had already developed CIPN and reported curative effects of RA-based prescriptions. The total effective rate of RA-based prescriptions was 79.07%, compared with 54.44% in the control group. Three trials compared curative effects of RA-based prescriptions plus mecobalamin to mecobalamin alone, where RA-based prescriptions were significantly more effective in relieving CIPN (*n* = 213 patients; OR, 4.84, 95% CI, 2.38 to 9.83, *P* \< 0.01). However, 1 trial compared RA-based prescription to mecobalamin, and 1 trial compared RA-based prescription to no treatment. In these trials, there was no statistical difference between groups.

### 3.4.4. SNCV and MNCV (Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}) {#sec3.4.4}

Six trials reported RA-based interventions significantly improved SNCV (MD 4.42 m/s, 95% CI 3.27 to 5.57, *P* \< 0.01). However, regarding MNCV, there was no statistical difference between groups.

### 3.4.5. Safety, Quality of Life, and Publication Bias {#sec3.4.5}

Among the 24 articles incorporated in the meta-analysis, no adverse events associated with RA-based interventions were reported. Nineteen trials reported Qol (KPS score \> 60 or ECOG score ≤ 2) before RA intervention, and 2 trials reported Qol improvement. One trial reported the percentage of patients with Qol improvement while the other reported the increased level of KPS score. Therefore, the results of these 2 trials could not be combined in the meta-analysis. Exploration of the funnel plots ([Figure 7](#fig7){ref-type="fig"}) for all-grade CIPN, high-grade CIPN, and curative effects between RA-based interventions and control suggested near symmetry. No significant publication bias was found.

4. Discussion {#sec4}
=============

CIPN is not recorded in classic TCM books, so it remains a big challenge for TCM oncologists. Based on syndrome differentiation and treatment, TCM oncologists believe that CIPN falls under the category of Bi syndrome in TCM. The pathogenesis of CIPN is believed to be asthenia of qi and blood, qi stagnation and blood stasis. These lead to tendon and vessel malnutrition and stasis in collaterals. The treatment includes benefiting qi and nourishing blood, regulating ying and wei, and promoting blood circulation to remove meridian obstruction.

RA is one of the most commonly used herbs tonifying qi.*In vitro* and*in vivo* studies suggest RA extract can be a potential nerve growth-promoting factor, being salutary in encouraging the growth of axons in peripheral nerves \[[@B36]\]. Astragaloside IV, an active ingredient in RA, contributed to sciatic nerve regeneration and functional recovery in mice. The mechanism underlying this effect may be associated with the upregulation of growth-associated protein-43 expression \[[@B37]\]. RA extract promoted neural-directed differentiation of mesenchymal stem cells into nerve cells*in vitro*and also had neuroprotective effects on the central nervous system \[[@B38], [@B39]\].

This review identified a relatively large amount of evidence on the effectiveness of RA-based interventions, either tested alone or tested in combined remedies, for the prevention and treatment of OXAL induced peripheral neuropathy. Compared with no intervention or conventional western medicine, RA-based interventions have the potential of being more effective in relieving CIPN. RA-based interventions also lead to improvement of SNCV. No adverse event was reported and 2 trials reported Qol improvement after RA-based interventions. In China, there is a general perception that it could improve Qol for various conditions. However, clinical trials need to monitor and report Qol improvement.

Most of RA-based prescriptions included Danggui, Guizhi, Baishao, Jixueteng, Chuanxiong, and Honghua. These herbs may improve the effects of RA intervention on CIPN. Individualized treatment in TCM requires the modification of herbs with various symptoms in different patients. So the herbs included in RA-based prescriptions were heterogeneous. There were variations in the formulation, dosage, administration, and duration of treatment in the included trials. Even for herbal intervention of the same name, there were still differences in the specific composition or dose of included Chinese herbal medicine. Information about quality control was lacking on the development of the herbal preparations or the manufacture of herbal products. Future trials should provide information about standardization, including composition, quality control, and detailed regimens. The majority of trials compared RA-based intervention with no intervention; others used western conventional medicine as controls. Only 1 trial used a formal placebo control, so the positive effect should be interpreted conservatively.

This review has its limitations. We only included studies published in journals. Dissertations and conference papers were not included. Only high quality (improved Jadad score ≥ 4 points) trials were included. We excluded 38 trials with low quality or insufficient information for assessing risk of bias. Therefore, it may not be possible to achieve a complete summary of all existent evidence. Quantitative subgroup analysis exploring the effects of age, disease history, and duration could not be performed due to insufficient data. No multicenter, large-scale RCTs were identified. Most trials focused on short-term rather than long-term outcomes. Future trials should assure adequate concealment of allocation and blinding of outcome assessors.

5. Conclusions {#sec5}
==============

From our study, we found that RA-based intervention may have clinical effectiveness for relieving OXAL induced peripheral neuropathy and lead to improvement of SNCV. However, the evidence is not sufficient. In the future, results from double-blind, multicenter, large-scale RCTs are needed to draw more definitive conclusions.
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###### 

Grading scales used to evaluate oxaliplatin-induced peripheral neuropathy.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Grade 1                                                     Grade 2                                                  Grade 3                                                  Grade 4
  -------------------------- ----------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------
  Levi et al. \[[@B31]\]     Paresthesia or insensitive, complete relief in 1 week       Paresthesia or insensitive, complete relief in 14 days   Paresthesia or insensitive, complete relief in 21 days   Paresthesia or insensitive,\
                                                                                                                                                                                                           combined with functional abnormality

                                                                                                                                                                                                           

  Miller et al. \[[@B32]\]   Paresthesias and/or decreased tendon reflex                 Severe paresthesia and/or mild anergia                   Intolerable paresthesia and/or marked motor loss         Paralysis

                                                                                                                                                                                                           

  CTCAE 4.03 \[[@B33]\]      Asymptomatic; loss of deep tendon reflexes or paresthesia   Moderate symptoms; limiting instrumental ADL             Severe symptoms; limiting self-care ADL                  Life-threatening consequences; urgent intervention indicated
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of studies included in this systematic review.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Author                    Year   Sample\   Mean age (year)\   \% men    Chemotherapy               Radix Astragali intervention   Control
                                   size      (median/range)                                                                         
  ------------------------- ------ --------- ------------------ -------- --------------------------- ------------------------------ -----------------
  Cui et al. \[[@B5]\]      2009   40        60                 57.5     FOLFOX                      Single herb extract            No intervention

  Feng \[[@B6]\]            2011   40        28*～*55           67.5     FOLFOX                      Compound prescription          No intervention

  Huang et al. \[[@B7]\]    2013   61        62.3               62.3     FOLFOX                      Compound prescription          No intervention

  Huang et al. \[[@B8]\]    2010   60        46                 71.7     FOLFOX                      Compound prescription          No intervention

  Jin et al. \[[@B9]\]      2015   77        47.2               48.1     FOLFOX                      Compound prescription          No intervention

  Kong \[[@B10]\]           2012   40        40*～*60           52.5     OXAL                        Compound prescription          No intervention

  Li et al. \[[@B11]\]      2013   60        50.1               31.7     FOLFOX                      Compound prescription          GSH

  Liang et al. \[[@B12]\]   2012   84        32*～*73           70.2     FOLFOX                      Compound prescription          No intervention

  Liang et al. \[[@B13]\]   2015   135       47.8               67.4     FOLFOX                      Compound prescription          No intervention

  Lin and Luo \[[@B14]\]    2011   90        51                 54.4     FOLFOX                      Compound prescription          No intervention

  Liu et al. \[[@B15]\]     2011   60        61.5               64.3     FOLFOX, OXAL                Compound prescription          Mecobalamin

  Liu \[[@B16]\]            2009   68        31*～*70           60.3     FOLFOX                      Compound prescription          No intervention

  Lv \[[@B17]\]             2015   90        53.0               53.3     OXAL                        Compound prescription          Mecobalamin

  Qin and Sun \[[@B18]\]    2015   42        55                 61.9     FOLFOX                      Compound prescription          Mecobalamin

  Qin et al. \[[@B19]\]     2012   68        57.2               47.1     OXAL, TAX                   Compound prescription          Cobamamide

  Shen et al. \[[@B20]\]    2015   60        59.7               65.0     OXAL                        Compound prescription          Mecobalamin

  Sun et al. \[[@B21]\]     2010   60        55.3               63.3     FOLFOX, XELOX, TAX + 5-Fu   Compound prescription          Mecobalamin

  Tan and Qi \[[@B22]\]     2015   63        31*～*70           60.3     OXAL                        Compound prescription          Mecobalamin

  Wang \[[@B23]\]           2015   60        52.3               50.0     FOLFOX                      Compound prescription          Ca/Mg infusions

  Wu et al. \[[@B24]\]      2015   89        49.2               70.8     Platinum, TAX,              Compound prescription          No intervention

  Wu et al. \[[@B25]\]      2012   60        23*～*71           65.8     FOLFOX                      Compound prescription          No intervention

  Wu et al. \[[@B26]\]      2015   60        59.7               65.6     Platinum, TAX, VCR          Compound prescription          No intervention

  Xu et al. \[[@B27]\]      2011   40        *∗*                45.0     OXAL                        Compound prescription          No intervention

  Zhang and Lu \[[@B28]\]   2013   70        31--77             65.7     FOLFOX                      Single herb extract +\         No intervention
                                                                                                     thioctic acid                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------

*FOLFOX*: oxaliplatin + 5-fluorouracil + calcium folinate.

*5-Fu*: 5-fluorouracil.

*GSH*: glutathione.

*OXAL*: oxaliplatin.

*TAX*: taxol.

*VCR*: vincristine.

*XELOX*: oxaliplatin + capecitabine.

###### 

Characteristics of Radix Astragali-based interventions.

  Author                    Year   Radix Astragali prescription    Administration     Course of treatment (d)            Dose (g)   Jadad score   CIPN grade   Curative effect   NCV    
  ------------------------- ------ ------------------------------- ------------------ ---------------------------------- ---------- ------------- ------------ ----------------- ----- ----
  Cui et al. \[[@B5]\]      2009   Huangqi Injection               i.v.               7                                  30 mL      4             \+                                   5
  Feng \[[@B6]\]            2011   Buyang Huanwu Decoction         ad us. ext         5 *∗* 6 chemotherapeutic cycles    120        4             \+                                   6
  Huang et al. \[[@B7]\]    2013   Huangqi Guizhi Wuwu Decoction   p.o.               5 *∗* 4 chemotherapeutic cycles    30         4             \+                                   7
  Huang et al. \[[@B8]\]    2010   Huangqi Guizhi Wuwu Decoction   ad us. ext         5 *∗* 4 chemotherapeutic cycles    100        4             \+                             \+    8
  Jin et al. \[[@B9]\]      2015   Self-made prescription          ad us. ext         10 *∗* 4 chemotherapeutic cycles   15         4             \+                                   9
  Kong \[[@B10]\]           2012   Self-made prescription          ad us. ext         6 *∗* 3 chemotherapeutic cycles    30         4             \+                                   10
  Li et al. \[[@B11]\]      2013   Self-made prescription          p.o.               5 *∗* 6 chemotherapeutic cycles    30         4             \+                                   11
  Liang et al. \[[@B12]\]   2012   Buyang Huanwu Decoction         p.o.               28                                 40         4             \+                                   12
  Liang et al. \[[@B13]\]   2015   Buyang Huanwu Decoction         p.o                28                                 30         4             \+                                   13
  Lin and Luo \[[@B14]\]    2011   Huangqi Guizhi Wuwu Decoction   ad us. ext         84                                 ≥15        4             \+                                   14
  Liu et al. \[[@B15]\]     2011   Huangqi Guizhi Wuwu Decoction   p.o.               42                                 30         4             \+                             \+    15
  Liu \[[@B16]\]            2009   Self-made prescription          ad us. ext         14                                 ≥15        4             \+                                   16
  Lv \[[@B17]\]             2015   Self-made prescription          ad us. ext         7                                  50         5                          \+                \+    17
  Qin and Sun \[[@B18]\]    2015   Self-made prescription          p.o.+ ad us. ext   14 *∗* 5 chemotherapeutic cycles   30         4             \+                                   18
  Qin et al. \[[@B19]\]     2012   Self-made prescription          ad us. ext         14                                 20         4                          \+                      19
  Shen et al. \[[@B20]\]    2015   Huangqi Guizhi Wuwu Decoction   ad us. ext         14                                 50         4                          \+                      20
  Sun et al. \[[@B21]\]     2010   Buyang Huanwu Decoction         ad us. ext         14                                 180        4                          \+                \+    21
  Tan and Qi \[[@B22]\]     2015   Self-made prescription          p.o.               10 *∗* 2 chemotherapeutic cycles   45         4                          \+                      22
  Wang \[[@B23]\]           2015   Huangqi Guizhi Wuwu Decoction   ad us. ext         3 *∗* 8 chemotherapeutic cycles    45         4             \+                                   23
  Wu et al. \[[@B24]\]      2015   Huangqi Guizhi Wuwu Decoction   p.o.               5 *∗* 4 chemotherapeutic cycles    30         4             \+                                   23
  Wu et al. \[[@B25]\]      2012   Buyang Huanwu Decoction         p.o.               112                                60         4             \+                             \+    25
  Wu et al. \[[@B26]\]      2015   Self-made prescription          p.o.               7 *∗* 2 chemotherapeutic cycles    ≥15        4             \+                                   26
  Xu et al. \[[@B27]\]      2011   Self-made prescription          ad us. ext         5 *∗* 2 chemotherapeutic cycles    30         4             \+                                   27
  Zhang and Lu \[[@B28]\]   2013   Huang qijing oral liquid        p.o.               5 *∗* 8 chemotherapeutic cycles    20         4             \+                             \+    28

###### 

Chinese herbs combination in Radix Astragali-based prescriptions.

  Latin name                             English name                  Chinese name   Counts   Frequency (%)
  -------------------------------------- ----------------------------- -------------- -------- ---------------
  *Angelica sinensis (Oliv.) Diels*      Radix Angelicae sinensis      Danggui        19       86.36
  *Cinnamomum cassia Presl*              Ramulus Cinnamomi             Guizhi         17       77.27
  *Paeonia lactiflora Pall.*             Radix Paeoniae Alba           Baishao        16       72.73
  *Spatholobus suberectus Dunn*          Caulis spatholobi             Jixueteng      13       59.09
  *Ligusticum chuanxiong Hort.*          Rhizoma Chuanxiong            Chuanxiong     12       54.55
  *Carthamus tinctorius L.*              Flos Carthami                 Honghua        10       50.00
  *Prunus persica (L.) Batsch*           Semen persicae                Taoren         9        40.91
  *Ziziphus jujuba Mill.*                Fructus Jujubae               Dazao          8        36.36
  *Salvia miltiorrhiza Bge.*             Radix Salviae Miltiorrhizae   Danshen        7        31.82
  *Zingiber officinale Rosc.*            Rhizoma Zingiberis (recens)   Jiang          7        31.82
  *Pheretima aspergillum (E. Perrier)*   Pheretima                     Dilong         7        31.82

[^1]: Academic Editor: Wenyi Kang
